Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 5/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.87 |
| ▸ | MEN1 | O00255 | 5/20 | 0.87 |
| ▸ | MAPT | P10636 | 5/20 | 0.87 |
| ▸ | RECQL | P46063 | 5/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.87 |
| ▸ | USP2 | O75604 | 4/20 | 0.87 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.87 |
| ▸ | APEX1 | P27695 | 4/20 | 0.87 |
| ▸ | BLM | P54132 | 4/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.87 |
| ▸ | HPGD | P15428 | 3/20 | 0.87 |
| ▸ | GALK1 | P51570 | 3/20 | 0.87 |
| ▸ | THRB | P10828 | 2/20 | 0.87 |
| ▸ | CASP1 | P29466 | 2/20 | 0.87 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.87 |
| ▸ | LMNA | P02545 | 2/20 | 0.87 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17206998 | 1.00 | BCL2 (0.97) | BCL2KDM4EMEN1MAPTRECQL | |
| SCHEMBL17206813 | 1.00 | BCL2 (0.97) | BCL2KDM4EMEN1MAPTRECQL | |
| SCHEMBL15683012 | 1.00 | BCL2 (0.97) | BCL2KDM4EMEN1MAPTRECQL | |
| SCHEMBL16440592 | 1.00 | BCL2 (0.97) | BCL2KDM4EMEN1MAPTRECQL | |
| SCHEMBL29373454 | 1.00 | BCL2 (0.97) | BCL2KDM4EMEN1MAPTRECQL | |
| Theaflavin Monogallates SCHEMBL13300897 | 0.98 | BCL2 (1.00) | BCL2KDM4EMEN1MAPTRECQL | |
| Theaflavin Monogallates SCHEMBL12792869 | 0.98 | BCL2 (1.00) | BCL2KDM4EMEN1MAPTRECQL | |
| Theaflavin Monogallates SCHEMBL13287115 | 0.98 | BCL2 (1.00) | BCL2KDM4EMEN1MAPTRECQL | |
| Theaflavin Monogallates SCHEMBL12672616 | 0.98 | BCL2 (1.00) | BCL2KDM4EMEN1MAPTRECQL | |
| Theaflavin Monogallates SCHEMBL12240727 | 0.98 | BCL2 (1.00) | BCL2KDM4EMEN1MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169231-B2 | Anti-obesity agent comprising compound containing benzotropolone ring | SUNTORY HOLDINGS LIMITED (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9169231-B2 | Anti-obesity agent comprising compound containing benzotropolone ring | SUNTORY HOLDINGS LIMITED (JP) | 2015-10-27 | — | — | US | disclosed |
| US-20150038573-A1 | ANTI-OBESITY AGENT COMPRISING COMPOUND CONTAINING BENZOTROPOLONE RING | SUNTORY HOLDINGS LIMITED (JP) | 2015-02-05 | — | — | US | disclosed |
| US-20150038573-A1 | ANTI-OBESITY AGENT COMPRISING COMPOUND CONTAINING BENZOTROPOLONE RING | SUNTORY HOLDINGS LIMITED (JP) | 2015-02-05 | — | — | US | disclosed |
| US-20140121388-A1 | ANTI-OBESITY AGENT COMPRISING COMPOUND CONTAINING BENZOTROPOLONE RING | SUNTORY HOLDINGS LIMITED (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121388-A1 | ANTI-OBESITY AGENT COMPRISING COMPOUND CONTAINING BENZOTROPOLONE RING | SUNTORY HOLDINGS LIMITED (JP) | 2014-05-01 | — | — | US | disclosed |
| US-8658237-B2 | Anti-obesity agent comprising compound containing benzotropolone ring | SUNTORY HOLDINGS LIMITED (JP) | 2014-02-25 | — | — | US | disclosed |
| US-8658237-B2 | Anti-obesity agent comprising compound containing benzotropolone ring | SUNTORY HOLDINGS LIMITED (JP) | 2014-02-25 | — | — | US | disclosed |
| US-20120065410-A1 | ANTI-OBESITY AGENT COMPRISING COMPOUND CONTAINING BENZOTROPOLONE RING | SUNTORY HOLDINGS LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065410-A1 | ANTI-OBESITY AGENT COMPRISING COMPOUND CONTAINING BENZOTROPOLONE RING | SUNTORY HOLDINGS LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065410-A1 | ANTI-OBESITY AGENT COMPRISING COMPOUND CONTAINING BENZOTROPOLONE RING | PNLIP, GAA, LIPC | BCL2 3696/4885KDM4E 1234/4885MEN1 4806/4885 |
| US-20150038573-A1 | ANTI-OBESITY AGENT COMPRISING COMPOUND CONTAINING BENZOTROPOLONE RING | PNLIP, GAA, LIPC | BCL2 3696/4885KDM4E 1234/4885MEN1 4806/4885 |
| US-20140121388-A1 | ANTI-OBESITY AGENT COMPRISING COMPOUND CONTAINING BENZOTROPOLONE RING | PNLIP, GAA, LIPC | BCL2 3696/4885KDM4E 1234/4885MEN1 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.